TTP – Patient Worthy

Caplacizumab Is Not Cost Effective for TTP Treatment

Post author:Kendall Mason
Post published:December 10, 2020
Post category:Thrombocytopenia

The Yale Cancer Center has recently presented the findings of their study of the cost-effectiveness of caplacizumab at the 62nc ASH Annual Meeting and Exposition. Their conclusion, which is that…

CLICK HERE TO SHARE YOUR STORY!

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Caplacizumab Is Not Cost Effective for TTP Treatment

Why Your Voice in Research Matters: Groundbreaking Studies are Changing What's Possible

Rethinking What It Means to Live With Acromegaly

The Let’s Chat CAR T One-on-One Mentor Program: Speaking with Someone Who Understands What You Are Going Through

Let’s Work Together!

Keep Up to Date

Learn More